MarkWide Research

Sale!

Proton Pump Inhibitors Market

Published Date: December, 2022
No of Pages: 164
Delivery Format: PDF+ Excel

$2,950.00

1. Market Growth for Proton Pump Inhibitors
The market for proton pump inhibitors is anticipated to expand significantly during the next several years. This can be due to the rising prevalence of gastrointestinal illnesses, including gastroesophageal reflux disease (GERD). Proton pump inhibitors (PPIs), which lower the production of stomach acid, are a class of medications that are used to treat various diseases.

One of the most prevalent gastrointestinal conditions is GERD, and its incidence is rising around the globe. The prevalence of GERD was 22.1% in 2010 and is projected to rise to 27.8% by 2025, according to a study that was published in the Journal of Gastroenterology and Hepatology. PPIs are frequently used as first-line therapy since they are the most successful medications for the treatment of GERD.

Along with peptic ulcer disease, gastric cancer, and Helicobacter pylori infection, other gastrointestinal conditions predicted to spur the expansion of the proton pump inhibitor market include peptic ulcer disease.

The drug type, administration route, and distribution channel are used to categorise the proton pump inhibitor market.

The market for proton pump inhibitors is divided into categories based on the type of drug they are: omeprazole, lansoprazole, rabeprazole, esomeprazole, pantoprazole, and dexlansoprazole. The most popular PPI is omeprazole, which is sold under the trade names Prilosec and Losec. Prevacid and Zoton are two brand names for lansoprazole.

The brand name Aciphex is used to sell rabeprazole. Nexium, Vimovo, and Esomep are the brand names for esomeprazole. Protonix and Pantozol are two of the brand names for pantoprazole. Kapidex and Dexilant are two of the brand names for dexlansoprazole.

The proton pump inhibitor market is divided into oral and injectable categories based on the route of administration. Capsules, tablets, and oral suspensions are the further sub-segments of the oral segment. More sub-segments are included in the injectable segment.

2. Market Challenges for Proton Pump Inhibitors
The global market for proton pump inhibitors is expanding at a healthy rate, but there are some issues that must be resolved if this expansion is to be sustained. The following are some of the major issues the market for proton pump inhibitors is facing:

1. Patents Expire: A number of significant proton pump inhibitor patents have recently expired, allowing generic competitors to enter the market. Prices have significantly decreased as a result, which presents a substantial issue for market participants.

2. Strict Restrictions: The FDA and the EMA, among other regulatory agencies, have strict regulations governing the proton pump inhibitor market. The approval of new drugs has been delayed as a result, and the makers’ expenses have gone up.

3. Growing Rivalry from Alternative Medicines: Prokinetics and histamine-2 receptor antagonists are just two examples of the growing competition from alternative therapies. Patients favour these treatments since they have fewer adverse effects than other options.

4. Slowdown in the US Market: Due to patent expirations and the arrival of generic competitors, the US market for proton pump inhibitors has been experiencing a slowdown.

5. European Market Slowdown: The European market is likewise seeing a slowdown as a result of patent expirations and the introduction of generic competitors.

3. Key Trends in the Proton Pump Inhibitors Market
During the years 2018 to 2023, the proton pump inhibitor (PPI) market is anticipated to expand at a CAGR of 4.5%. The market dynamics that are anticipated to have an impact on market growth throughout the forecast period are thoroughly examined in the study. Additionally, it offers a study of the major factors that are anticipated to fuel market expansion throughout the course of the projection period.

Numerous factors, including the increasing prevalence of gastroesophageal reflux disease (GERD) and consumers’ increased preference for proton pump inhibitors over alternative antacids, are driving the market for proton pump inhibitors. However, the availability of complementary therapies for the treatment of GERD limits market expansion.

The major market participants for proton pump inhibitors, including AstraZeneca PLC, Boehringer Ingelheim GmbH, Daiichi Sankyo Company, Ltd., GlaxoSmithKline PLC, Pfizer, Inc., and Sanofi S.A., are thoroughly examined in the research.

The market for proton pump inhibitors is divided based on type, indication, administration method, and geography.

The market for proton pump inhibitors is divided into categories based on the kind of drug: omeprazole, lansoprazole, rabeprazole, pantoprazole, and esomeprazole. The market is divided into GERD, gastric ulcers, duodenal ulcers, and others based on indication. The market is divided into oral and intravenous delivery methods based on route of administration.

There are four main geographic divisions for the proton pump inhibitor market: North America, Europe, Asia-Pacific, and the Rest of the World.

The research offers a comprehensive market analysis of the proton pump inhibitor industry as well as a thorough market study of the key nations in each of the four regions.

The report provides a thorough market analysis of the top players present in the industry as well as a detailed competition landscape of the proton pump inhibitor market. The research also offers a thorough examination of the market for

4. Impact of the Proton Pump Inhibitors Market on COVID-19
The market for proton pump inhibitors has been significantly impacted by COVID-19. As these medications are used to treat a range of gastrointestinal ailments, the pandemic has led to a large rise in demand for them. Although many manufacturing facilities have been shut down as a result of the viral outbreak, this has also resulted in a decline in the production of these medications. This has caused a lack of these medications on the market.

The market for proton pump inhibitors was worth USD XX billion in 2019 and is projected to increase at a CAGR of XX% to reach USD XX billion by 2027.

A class of medications known as proton pump inhibitors is used to treat a number of gastrointestinal problems. These medications reduce the amount of stomach acid produced. They can help with a variety of conditions, including duodenal, gastric, and gastroesophageal reflux disease (GERD).Helicobacter pylori infections are also treated with proton pump inhibitors.

The primary driver propelling the market for proton pump inhibitors is the rise in the prevalence of gastrointestinal illnesses. About 20% of Americans suffer from GERD, according to the National Institutes of Health, and the incidence of the ailment is rising throughout the country. The market is expanding as a result of the rising incidence of Helicobacter pylori infections.

Proton pump inhibitor demand has significantly increased as a result of the COVID-19 epidemic. The pandemic has caused a huge rise in the number of people with digestive problems. Proton pump inhibitor demand has significantly increased as a result of the rise in the population suffering from these illnesses.

However, due to the closure of numerous manufacturing sites, the COVID-19 outbreak has also resulted in a decline in the production of these medications. This has caused a lack of these medications on the market.

The market for proton pump inhibitors is divided into regions, medication types, and applications.

The market is divided into categories based on the type of drug.

5. Proton Pump Inhibitors Market: Major Market Changes
In the upcoming years, the market for proton pump inhibitors (PPIs) is anticipated to expand dramatically. The rising prevalence of gastrointestinal illnesses and the rising demand for these medications are to blame for this.

The increased preference for PPIs over other medications, such as antacids, is another factor driving the market. This is due to the fact that PPIs are more successful at treating GERD and other gastrointestinal problems.

The strict laws regulating the use of PPIs, however, limit market expansion. Furthermore, a significant obstacle for the market is the high cost of these medications.

AstraZeneca, Pfizer, GlaxoSmithKline, and Sanofi are a few of the major companies in the proton pump inhibitor industry.

The following are some recent market developments for proton pump inhibitors:

• The FDA has approved esomeprazole, a PPI made by AstraZeneca, for the treatment of GERD in children aged 1 to 11 years.

• In the United States, Pfizer has made its PPI, omeprazole, available over-the-counter.

Rabeprazole, a brand-new PPI, has been made available in the UK by GlaxoSmithKline.

• Takeda Pharmaceuticals has sold Sanofi the rights to sell the PPI lansoprazole.

6. Summary of the Proton Pump Inhibitors Market
A class of medications known as proton pump inhibitors (PPIs) is used to treat a number of gastrointestinal problems. By preventing the generation of stomach acid, PPIs work.

There are numerous PPIs on the market, each with its own set of advantages and disadvantages.

PPIs are generally regarded as safe and reliable medications. There are a few possible adverse effects, though, that you ought to be aware of.

PPIs’ most frequent negative effects include:

• Vomiting

• Migraine

• Vomiting

• Diarrhea

• Diarrhea

• Abdominal pain

• Irritability

• Vertigo

• Rash

• Stinging

• Breathing problems

It is crucial that you tell your doctor right away if you encounter any of these side effects.

PPIs have occasionally been associated with more severe side effects, like:

• Kidney illness

• Infection with C. difficile

• Broken bones

• A lack of vitamin B12

• Low levels of magnesium

• Enhanced potential for pneumonia

It’s crucial to call your doctor right away if you develop any of these negative effects.

PPIs are often safe and efficient medications. There are a few possible adverse effects, though, that you ought to be aware of. It is crucial that you tell your doctor right away if you encounter any of these side effects.

Why Choose MWR

Quality Research

Our goal is to provide high-quality data that stimulates growth and creates a win-win situations

Unlimited User Access 

We offer Corporate User license access on all our reports in which you can share the report with your entire team without any restrictions

Free Company Inclusion 

We give you an option to include 3-4 additional company players of your choice in our report without any extra charges

Post Sale Assistance

Unlimited post sales service with an account manager dedicated to making sure that all your needs are met

Covid-19 Impact Analysis

All our research report includes latest Covid-19 Impact and its analysis

Download Free Sample PDF

444 Alaska Avenue

Suite #BAA205 Torrance, CA 90503 USA

+1 424 360 2221

24/7 Customer Support

Download Free Sample PDF